Dr Walid Qoronfleh, Director of Research and Policy Development at the World Innovation Summit for Health

Researchers from the World Innovation Summit for Health (WISH), an initiative of Qatar Foundation, and Hamad Medical Corporation (HMC) have developed a molecular diagnostic technique that enables cancer testing at the genetic level for the first time. The Molecular Diagnostic Kit (MDx), which has been completely funded and developed in Qatar, is a novel technology that provides personalised diagnosis of blood cancer. The newly-developed kit can determine the severity of the cancer and monitor a patient as they undergo treatment.

Blood cancer is currently the most prevalent type of cancer in the region. The MDx prototype has been entirely developed in Qatar by Dr Nader Al Dewik, Qatar Medical Genetic Center at HMC, in collaboration with Dr Walid Qoronfleh, Director of Research and Policy, WISH, as part of the Applied Biomedicine Initiative, funded by Qatar Science & Technology Park’s Accelerator Program. The goal of the Applied Biomedicine Initiative is to leverage data collected by the Qatar Genome Programme in the future, to develop further diagnostic kits applicable to hereditary and metabolic disorders. These types of initiatives have ramifications for Qatar’s healthcare management at a policy level.

This prototype was designed specifically for the population of Qatar and the region, as it takes into account the unique genetic makeup of people from the region. The MDx Kits will further facilitate progression towards precision medicine that offers tailored therapeutic treatment to patients.

Both Qatar-based researchers have recently published an article titled ‘Genomics Medicine Innovations: Trends Shaping the Future of Healthcare and Beyond’, highlighting the development of the innovative bespoke kit, in the International Journal of Advanced Research.

Dr Qoronfleh has also developed, in collaboration with MS Bioworks LLC (USA), and NextGen Sciences, Inc. (USA), the concept of a novel mass spectrometry workflow that measures multiple proteins simultaneously, thereby making the process cost- and time-effective. The workflow permits protein biomarker discovery and confirmation and may be used in critical decision-making processes such as patient and drug dose selection. The multiplex panel can process up to a 100 proteins simultaneously and has positive implications for scientists and medical practitioners looking to use bodily fluids to diagnose not only cancer but diseases affecting the central nervous system, particularly Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis.

To view the article on the MDx Kit, Genomics Medicine Innovations: Trends Shaping the Future of Healthcare and Beyond, click here.